Affimed N.V. (LON:0HL9)
0.8119
+0.0323 (4.14%)
At close: Apr 24, 2025
Affimed Revenue
Affimed had revenue of 164.00K EUR in the quarter ending September 30, 2024, a decrease of -91.62%. This brings the company's revenue in the last twelve months to 5.64M, down -72.92% year-over-year. In the year 2023, Affimed had annual revenue of 13.91M, down -67.39%.
Revenue (ttm)
5.64M EUR
Revenue Growth
-72.92%
P/S Ratio
2.45
Revenue / Employee
74.17K EUR
Employees
76
Market Cap
11.51M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 13.91M | -28.76M | -67.39% |
Dec 31, 2022 | 42.67M | 1.12M | 2.70% |
Dec 31, 2021 | 41.55M | 12.69M | 43.99% |
Dec 31, 2020 | 28.86M | 7.43M | 34.66% |
Dec 31, 2019 | 21.43M | -2.30M | -9.68% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
GSK plc | 31.38B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Oxford Nanopore Technologies | 183.19M |
Affimed News
- 4 days ago - Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting - GlobeNewsWire
- 7 days ago - Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement - GlobeNewsWire
- 4 weeks ago - Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting - GlobeNewsWire
- 2 months ago - Affimed to Present at the Leerink Partners Global Healthcare Conference 2025 - GlobeNewsWire
- 4 months ago - Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC) - Benzinga
- 4 months ago - Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) - GlobeNewsWire
- 4 months ago - Affimed reports data from mid-stage study of its lymphoma treatment - Seeking Alpha
- 5 months ago - Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer - GlobeNewsWire